Lactate dehydrogenase isozymes in human cardiac transplantation

Science
J J NoraJ D Milam

Abstract

Lactate dehydrogenase (LDH) isozyme activities have been followed in 17 human cardiac allografts. A pattern of abnormality associated with cardiac rejection during the first month after operation has been determined: (i) LDH-1 activity is greater than LDH-2 activity; (ii) LDH-1 activity is greater than 35 percent of total LDH activity; and (iii) LDH-1 activity is greater than 100 international units. The LDH-1 abnormality helps to meet the need for an index of cardiac rejection during the early weeks after operation when the electro-cardiogram is least reliable.

References

Jul 1, 1967·Transplantation·N E ShumwayR D Wuerflein
Dec 1, 1968·The American Journal of Cardiology·D A CooleyR D Leachman
May 15, 1969·The New England Journal of Medicine·J J NoraJ J Trentin
Sep 1, 1958·American Journal of Clinical Pathology·P G CABAUD, F WROBLEWSKI
Jul 1, 1962·Clinica Chimica Acta; International Journal of Clinical Chemistry· VAN DER KOOI, MW
Mar 1, 1965·American Journal of Clinical Pathology·J A PRESTONJ G BATSAKIS
May 1, 1959·Proceedings of the National Academy of Sciences of the United States of America·C L Markert, F Møller

❮ Previous
Next ❯

Citations

Jan 1, 1969·Langenbecks Archiv für Chirurgie·D A CooleyD G Rochelle
Jan 1, 1970·Journal of Clinical Pathology. Supplement (Association of Clinical Pathologists)·S B Rosalki
Jan 1, 1972·Scandinavian Journal of Thoracic and Cardiovascular Surgery·B K Semb, J H Stromme
Oct 1, 1969·The American Journal of Cardiology·J D Haller, M M Cerruti
Oct 1, 1969·Postgraduate Medicine·L L LeathermanG M Lemole

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.